ASCO 2024 Conference Intelligence Around HER2 Negative Breast Cancer Assets
ASCO 2024 Conference Intelligence Around HER2 Negative Breast Cancer Assets
DelveInsight partnered with a leading US-based pharmaceutical company to deliver end-to-end strategic conference intelligence focused on HER2-negative breast cancer drug development at ASCO 2024 (American Society of Clinical Oncology Annual Meeting). The goal was to capture real-time competitive insights—ranging from product-level details and R&D updates to pipeline milestones, future development trajectories, and key opinion leader (KOL) perspectives. This comprehensive support empowered the client to maintain competitive awareness, guide strategic planning, and proactively address emerging scientific and market dynamics within the fast-evolving HER2-negative breast cancer landscape.
ASCO is an enormous scientific forum, featuring thousands of abstracts, posters, and parallel sessions. For a company tracking HER2-negative breast cancer—one of the most competitive therapeutic areas—monitoring every relevant update while filtering meaningful intelligence from noise is highly challenging without specialized, dedicated support.
Beyond simple data capture, the client required a strategic intelligence framework that included:
Pre-congress planning to pinpoint high-value presentations and abstracts
Real-time session tracking to document clinical data, milestones, and competitive messaging
Primary research including KOL interviews and on-ground insight gathering
Strategic synthesis aligned with internal KITs (Key Intelligence Topics) and KIQs (Key Intelligence Questions)
Rapid insights delivery to ensure leadership could respond with agility
👉 Explore how DelveInsight delivers real-time, high-impact conference intelligence:
https://www.delveinsight.com/case-study/conference-intelligence-product-assessment?utm_source=casestudy&utm_medium=promotion&utm_campaign=mpr
DelveInsight implemented a robust, multi-layered approach—combining curated pre-congress planning, real-time monitoring, KOL research, and strategic insight generation—to ensure maximum relevance and value.
To equip the client with actionable intelligence, DelveInsight designed a tailored conference coverage blueprint that included:
Systematic program review: Extracting every ASCO 2024 session, abstract, oral presentation, and poster relevant to HER2-negative breast cancer
Priority classification: Evaluating sessions for competitive impact, data novelty, and strategic alignment
Resource optimization: Assigning real-time coverage for high-priority sessions and structured post-event analysis for secondary sessions
👉 See how our tailored conference analysis can elevate competitive strategy:
https://www.delveinsight.com/case-study/conference-intelligence-product-assessment?utm_source=casestudy&utm_medium=promotion&utm_campaign=mpr
DelveInsight’s experts conducted targeted primary research to complement quantitative findings with deep qualitative insights. Activities included:
Interviewing KOLs for interpretations of clinical results and competitive implications
Speaking with researchers, clinicians, and industry stakeholders to contextualize data
Capturing unbiased expert commentary on regulatory direction, clinical differentiation, and commercial potential
During the conference, the team delivered:
Comprehensive session documentation: Clinical trial design, efficacy/safety updates, population insights, regulatory updates, and future R&D plans
Strategic business analysis: Identification of competitive threats, emerging opportunities, and portfolio implications
KIQ/KIT-driven intelligence: Ensuring insights directly supported the client’s internal strategic priorities
DelveInsight provided immediate, high-value intelligence to senior stakeholders throughout ASCO 2024. These updates enabled leadership to:
Reassess pipeline priorities
Respond promptly to competitor announcements
Identify potential licensing or collaboration opportunities
Communicate with investors and partners from a well-informed position
The engagement delivered several critical outcomes:
1. Proactive Competitive Response
The company could evaluate competitor data, adjust priorities, and explore partnerships—during the congress rather than weeks later.
2. Timely, Insight-Rich Leadership Communication
Key internal groups received continuous updates, empowering them to act swiftly on emerging intelligence.
3. Comprehensive Intelligence Repository
The post-congress package included:
Detailed clinical data summaries
R&D timelines and product profiles
KOL-derived insights
Competitive assessments
Strategic recommendations
4. Enhanced Strategic Advantage
By outsourcing to DelveInsight, the client gained expert-level intelligence without diverting internal teams or resources.
👉 Learn how DelveInsight supports global pharma teams with specialized conference intelligence:
https://www.delveinsight.com/case-study/conference-intelligence-product-assessment?utm_source=casestudy&utm_medium=promotion&utm_campaign=mpr